LEXINGTON, Ky. (WKYT) - RSV is the leading cause of hospitalization for U.S. infants, according to the CDC. Now, they say a ...
GSK has received approval from Japan’s MHLW for RSV vaccine Arexvy to prevent RSV disease in adults aged over 60 years ...
The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...
GSK plc has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory ...
Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, that can help to protect infants through the active immunisation ...
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect ...
In a nearly unanimous vote, advisors to the Centers for Disease Control and Prevention have recommended a new vaccine to ...
New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...
U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns. The Centers ...
Health Minister Stephen Donnelly will update the Cabinet this morning about plans to deal with viruses circulating this ...
GSK plc (GSK, GSK.L) said Japan's Ministry of Health, Labour and Welfare has approved Arexvy for the prevention of respiratory ...
(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...
